The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease

Denosumab treatment was more efficacious than treatment with zoledronic acid in delaying or preventing HCM in advanced cancer patients with breast cancer, other solid tumours or multiple myeloma.